Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain
Data(s) |
01/04/2003
|
---|---|
Resumo |
The present investigation was performed to evaluate the susceptibility of seven clones isolated from the highly resistant Colombian strains, prototype of Biodeme Type III. Seven clones previously obtained, showed a phenotypic homogeneity and high similarity with the parental strain. Eight groups of 30 mice were inoculated with one of seven clones or the parental strain; 20 were treated with benznidazole (100mg/kg/day) and 10 were untreated controls. Cure evaluations were done by parasitological and serological tests and PCR. Cure rates varied from 0% (null) to 16.7%. Correlation between positivity of parasitological and serological tests with positive PCR reached 37%. The results demonstrated the high resistance of the clones, suggesting the predominance of a highly resistant principal clone in this strain. The findings apparently indicate that the possibility of cure is minimal for patients infected with this biodeme; a fact that could affect the control of Chagas' disease through treatment of chronically infected people. |
Formato |
text/html |
Identificador |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822003000200002 |
Idioma(s) |
en |
Publicador |
Sociedade Brasileira de Medicina Tropical - SBMT |
Fonte |
Revista da Sociedade Brasileira de Medicina Tropical v.36 n.2 2003 |
Palavras-Chave | #Chagas' disease #Trypanosoma cruzi #Clones #Chemotherapy #Resistance #Benznidazole |
Tipo |
journal article |